Compositions
AssigneeVHsquared Limited
InventorsScott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
Life of this patent
Estimating the term…
Abstract
There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
Claims24
A solid pharmaceutical composition comprising a compressed core, wherein the compressed core comprises:
- (i) two or more pharmaceutically active binding polypeptides connected by one or more linkers, wherein the two or more pharmaceutically active binding polypeptides are present at 40-75% by weight relative to the weight of the core,
- (ii) one or more compression aids wherein the one or more compression aids is present at 20-55% by weight relative to the weight of the core,
- (iii) one or more disintegrants wherein the one or more disintegrants is present at 2-6% by weight relative to the weight of the core wherein the compressed core is coated with a pH sensitive enteric coating and wherein the two or more pharmaceutically active binding polypeptides are immunoglobulins or immunoglobulin fragments.
A method of delivering two or more pharmaceutically active binding polypeptides to a region of the intestinal tract comprising orally administering a solid pharmaceutical composition comprising a compressed core, wherein the compressed core comprises:
- (i) the two or more pharmaceutically active binding polypeptides connected by one or more linkers, wherein the two or more pharmaceutically active binding polypeptides are present at 40-75% by weight relative to the weight of the core,
- (ii) one or more compression aids wherein the one or more compression aids is present at 20-55% by weight relative to the weight of the core,
- (iii) one or more disintegrants wherein the one or more disintegrants is present at 2-6% by weight relative to the weight of the core wherein the compressed core is coated with a pH sensitive enteric coating and wherein the two or more pharmaceutically active binding polypeptides are immunoglobulins or immunoglobulin fragments.
Dependencies are inferred from the claim text.